ArticleTranslational cancer research2020
Comprehensive analysis of the
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Article
- Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach.NAR cancer · 2025Article
- Mechanistic Insights into Drug-Induced Guillain-Barré Syndrome: A Large-Cohort Analysis of the FAERS Database.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Unsupervised Random Forest Identifies Important Genetic Prognostic Factors for Breast Cancer Survival Time.Cancer informatics · 2025Article
- Comprehensive Mendelian randomization and colocalization analysis of plasma proteomics to identify new therapeutic targets for bladder cancer.Journal of Cancer · 2025Article
- Article
- PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases.Cancer metastasis reviews · 2024Review
- Computational analysis of the functional impact of MHC-II-expressing triple-negative breast cancer.Frontiers in immunology · 2024Article
- Mitochondrial-related genes as prognostic and metastatic markers in breast cancer: insights from comprehensive analysis and clinical models.Frontiers in immunology · 2024Article
- LINC01116 affects patient survival differently and is dissimilarly expressed in ER+ and ER- breast cancer samples.Cancer reports (Hoboken, N.J.) · 2023Article
- Identification of a gene expression signature associated with breast cancer survival and risk that improves clinical genomic platforms.Bioinformatics advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increasing amount of research over recent years on the anti-metastasis function of the non-metastatic (
methodsIn this study, ONCOMINE, GEPIA, Kaplan-Meier plotter, cBioPortal, String, and metascape databases were utilized for comparison of the mRNA expression, patient survival and network analysis of NME-associated signaling pathways in BC patients.
resultsThe mRNA expression of NME1 and NME2 was significantly increased in BC. Additionally, high NME 1 and NME2 levels were related to poor overall survival (OS), while the upregulated expression of NME3, NME5, and NME7 indicated prolonged survival. Moreover, increased mRNA level, amplification, or deep deletions in the NME gene family were identified in approximately 41% (450/1098) of all included BC specimens.
conclusionsCollectively, our findings revealed that the elevated expression of NME1 and NME2 could act as a biomarker and predictive tool for BC patients with poor prognosis. Furthermore, our findings indicated that NME3, NME5, and NME7 might play the roles of tumor suppressor genes, which require validation through further experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.